Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospekta in cognitive disorders after ischemic stroke
NCT04295681Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Dec 2019
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of Prospekta in cognitive disorder (CD), sponsored by Materia Medica Holding. Started Dec 2019; status: completed.
02
Drugs
Prospekta
03
Conditions
cognitive disorder (CD)
Beyond the preview
Go deeper on NCT04295681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295681.